**11. Conclusions**

Demonstration of statistically significant relationship between HIF-1 α expression and tumor size (pT) in patients diagnosed with triple-negative breast cancer with lymph node metastases, may suggest that HIF-1 α expression in this group of patients may be an additional and significant marker in the evaluation of advance of the disease, affecting therapeutic decisions.

[8] Montagna E, Maisonneuve P, Rotmensz N, et al. Heterogeneity of triple-negative breast cancer: Histologic subtyping to inform the outcome. Clinical Breast Cancer. 2013;**13**:31-39

Triple-Negative Breast Cancer: Expression of Hypoxia-Inducible Factor 1α in Triple-Negative…

http://dx.doi.org/10.5772/intechopen.75354

95

[9] Somali I, Ustaoglu BY, Tarhan MO, et al. Clinicopathologic and demographic evaluation of triple-negative breast cancer patients among a Turkish patient population: A single

center experience. Asian Pacific Journal of Cancer Prevention. 2013;**14**:6013-6017

2008;**26**:4282-4288

the art. Tumori. 2010;**96**:875-888

Frontiers in Oncology. 2013;**3**:250

Breast, Lyon. IARC; 2012

2012;**21**:20-26

Oncologist. 2016;**21**:1050-1062

of Clinical Investigation. 2011;**121**:2750-2767

[10] Atchley D, Albarracin C, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. Journal of Clinical Oncology.

[11] Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: A complex and deadly molecular

[12] Rastelli F, Biancanelli S, Falzetta A, et al. Triple-negative breast cancer: Current state of

[13] Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal

[14] den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention.

[15] Lakhani SR, Ellis IO, Schnitt SJ, et al. editors. WHO Classification of Tumours of the

[16] Criscitiello C, Azim HA Jr, Schouten PC, et al. Understanding the biology of triple-neg-

[17] Rosen PP, Hoda SA. Breast Pathology. Diagnosis by Needle Core Biopsy.3rd ed. Phila-

[18] Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: A clinicopatho-

[19] Eiermann W, Bergh J, Cardoso F, et al. Triple negative breast cancer: Proposals for a pragmatis definition and implications for patient management and trial design. Breast.

[20] Arpino G, Clark GM, Mohsin S, et al. Adenoid cystic carcinoma of the breast: Molecular

[21] Sharma P. Biology and management of patients with triple-negative breast cancer. The

[22] Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research. 2007;**13**:2329-2334

[23] Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer:

ative breast cancer. Annals of Oncology. 2012;**23**(Suppl 6):vi13-vi18

delphia: Wolters Kluwer, Lippincott Wiliams & Wilkins; 2010

logic study with 10 year follow-up. Cancer. 1977;**40**:1365-1385

markers, treatment, and clinical outcome. Cancer. 2002;**94**:2119-2127

A retrospective multicenter study. Annals of Oncology. 2015;**26**:1518

subtype. Current Molecular Medicine. 2012;**12**:96-110
